Skip to main content
. 2022 Feb 7;68(6):772–778. doi: 10.1097/MAT.0000000000001666

Table 3.

Use of COVID-19-specific Interventions in the Study Cohorts

Patients survived
(n = 7)
Deceased patients
(n = 10)
p value
Remdesivir, n 5 (71%) 6 (60%) 0.65
Convalescent plasma, n 3 (43%) 5 (50%) 0.79
Dexamethasone, n 3 (43%) 10 (100%) 0.004
Tocilizumab, n 6 (86%) 6 (60%) 0.28